Bioactive nanoparticles from clam extracts mitigate alcoholic liver injury by modulating multiple pathways.

Area of Science:

• Biomedical Science
• Nanotechnology
• Hepatology

Background:

• Alcoholic fatty liver disease (AFLD) is a significant global health issue.
• Ethanol consumption leads to liver damage through steatosis, inflammation, and oxidative stress.
• Clam extracts possess hepatoprotective properties due to their bioactive compounds.

Purpose of the Study:

• To investigate the therapeutic potential of clam (Geloina erosa)-derived nanoparticles (CNPs) against AFLD.
• To characterize CNPs and evaluate their effects on ethanol-induced liver injury in mice.

Main Methods:

• CNPs were isolated using tangential flow filtration and characterized for size and charge.
• Ethanol-fed mice were orally administered CNPs for nine weeks.
• Hepatic inflammation, lipid metabolism, antioxidant defenses, and ethanol detoxification pathways were analyzed.

Main Results:

• CNPs (62.2 nm, negative charge) significantly reduced ethanol-induced liver injury.
• CNPs modulated inflammation (TLR4/MyD88), rebalanced lipids (SREBP-1c, PPARα), and restored antioxidant defenses (Nrf2/HO-1).
• CNPs enhanced ethanol detoxification (ADH, ALDH, CYP2E1) and promoted M2 macrophage polarization, supporting gut-liver axis activity.

Conclusions:

• CNPs act as effective nanocarriers for delivering bioactive compounds to mitigate AFLD.
• CNPs offer a multifunctional therapeutic strategy by targeting multiple pathological pathways in AFLD.
• Further research into CNPs could lead to novel treatments for liver diseases.